| 1 |
Kunert JP, Müller M, Günther T, Stopper L, Urtz-Urban N, Beck R, Wester HJ. Synthesis and preclinical evaluation of novel (99m)Tc-labeled PSMA ligands for radioguided surgery of prostate cancer. EJNMMI Res 2023;13:2. [PMID: 36645586 DOI: 10.1186/s13550-022-00942-7] [Reference Citation Analysis]
|
| 2 |
Kroenke M, Schweiger L, Horn T, Haller B, Schwamborn K, Wurzer A, Maurer T, Wester HJ, Eiber M, Rauscher I. Validation of (18)F-rhPSMA-7 and (18)F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer. J Nucl Med 2022;63:1809-14. [PMID: 35393348 DOI: 10.2967/jnumed.121.263707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 3 |
Knorr K, Oh SW, Krönke M, Wurzer A, D'Alessandria C, Herz M, Weber W, Wester HJ, Eiber M, Yusufi N, Nekolla S. Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3. EJNMMI Res 2022;12:8. [PMID: 35119557 DOI: 10.1186/s13550-021-00872-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Depalatis L, Martiniova L, de Almeida Graff T, Ravizzini G. Applications of PSMA-PET in tumors other than prostate cancer. Nuclear Medicine and Molecular Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00116-2] [Reference Citation Analysis]
|
| 5 |
Malaspina S, Taimen P, Kallajoki M, Oikonen V, Kuisma A, Ettala O, Mattila K, Boström PJ, Minn H, Kalliokoski K, Postema EJ, Miller MP, Scheinin M. Uptake of 18 F-rhPSMA-7.3 in Positron Emission Tomography Imaging of Prostate Cancer: A Phase 1 Proof-of-Concept Study. Cancer Biotherapy and Radiopharmaceuticals. [DOI: 10.1089/cbr.2021.0322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 6 |
Neels OC, Kopka K, Liolios C, Afshar-Oromieh A. Radiolabeled PSMA Inhibitors. Cancers (Basel) 2021;13:6255. [PMID: 34944875 DOI: 10.3390/cancers13246255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 7 |
Petrov SA, Zyk NY, Machulkin AE, Beloglazkina EK, Majouga AG. PSMA-targeted low-molecular double conjugates for diagnostics and therapy. Eur J Med Chem 2021;225:113752. [PMID: 34464875 DOI: 10.1016/j.ejmech.2021.113752] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 8 |
Bailey JJ, Wuest M, Wagner M, Bhardwaj A, Wängler C, Wängler B, Valliant JF, Schirrmacher R, Wuest F. Synthesis and Preclinical Evaluation of [18F]SiFA-PSMA Inhibitors in a Prostate Cancer Model. J Med Chem 2021;64:15671-89. [PMID: 34672630 DOI: 10.1021/acs.jmedchem.1c00812] [Reference Citation Analysis]
|
| 9 |
Yusufi N, Wurzer A, Herz M, D'Alessandria C, Feuerecker B, Weber W, Wester HJ, Nekolla S, Eiber M. Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using 19F/177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T. J Nucl Med 2021;62:1106-11. [PMID: 33443072 DOI: 10.2967/jnumed.120.254516] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Reissig F, Bauer D, Zarschler K, Novy Z, Bendova K, Ludik MC, Kopka K, Pietzsch HJ, Petrik M, Mamat C. Towards Targeted Alpha Therapy with Actinium-225: Chelators for Mild Condition Radiolabeling and Targeting PSMA-A Proof of Concept Study. Cancers (Basel) 2021;13:1974. [PMID: 33923965 DOI: 10.3390/cancers13081974] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 11 |
Malaspina S, Oikonen V, Kuisma A, Ettala O, Mattila K, Boström PJ, Minn H, Kalliokoski K, Postema EJ, Miller MP, Scheinin M. Kinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging 2021. [PMID: 33846844 DOI: 10.1007/s00259-021-05346-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 12 |
Rauscher I, Karimzadeh A, Schiller K, Horn T, D'Alessandria C, Franz C, Wörther H, Nguyen N, Combs SE, Weber WA, Eiber M. Detection efficacy of 18F-rhPSMA-7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment. J Nucl Med 2021:jnumed. [PMID: 33712531 DOI: 10.2967/jnumed.120.260091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 13 |
Wurzer A, Di Carlo D, Herz M, Richter A, Robu S, Schirrmacher R, Mascarin A, Weber W, Eiber M, Schwaiger M, Wester HJ. Automated synthesis of [18F]Ga-rhPSMA-7/ -7.3: results, quality control and experience from more than 200 routine productions. EJNMMI Radiopharm Chem 2021;6:4. [PMID: 33484364 DOI: 10.1186/s41181-021-00120-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
